Mycobacterium tuberculosis infection in patients with cystic fibrosis (CF) is rare. We report a 22-year-old CF patient with high fever, dyspnea and weight loss that progressively worsened over 2 weeks before admission. The patient suffered from liver cirrhosis, was colonized with Pseudomonas aeruginosa and had been repeatedly hospitalized for pulmonary infections. The patient was treated initially as for an exacerbation of P. aeruginosa infection, but tuberculosis (TBC) was suspected due to lack of improvement. A CT of the chest revealed enlarged bilateral cavities in the upper and middle lobes. A tuberculin skin test was positive, and M. tuberculosis nucleic acid was isolated from sputum samples. After receiving first-line anti-TBC drugs for 1 month, the patient's condition continued to worsen so molecular drug susceptibility testing was performed. Multidrug-resistant TBC was discovered, leading to a change in regimen. The patient was treated with ethionamide, moxifloxacin, linezolid, amikacin, imipenem/cilastatin and rifabutin and showed a remarkable clinical improvement. Although nontuberculous mycobacteria are more common in CF, the possibility of TBC should not be ignored. In that setting, early suspicion of infection due to resistant M. tuberculosis can be life saving.

Keywords:
Cystic fibrosis, Tuberculosis, Multidrug resistance
1.
Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, Bellis G, Vibet MA, Le Roux E, Lemonnier L, Gutierrez C, Vincent V, Fauroux B, Rottman M, Guillemot D, Gaillard JL, Hermann JL: Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009;47:4124-4128.
2.
Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR: Nontuberculous mycobacteria. I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828-834.
3.
Oliver A, Maiz L, Canton R, Escobar H, Baquero F, Gomez-Mampaso E: Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001;32:1298-1303.
4.
Sexton P, Harrison AC: Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008;31:1322-1333.
5.
Koch C, Hoiby N: Diagnosis and treatment of cystic fibrosis. Respiration 2000;67:239-247.
6.
Wood RE, Boat RF, Doershuk CF: Cystic fibrosis. Am Rev Respir Dis 1976;113:833-878.
7.
Smith MJ, Efthimiou J, Hodson ME, Batten JC: Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984;39:369-375.
8.
Hjelte L, Petrini B, Kallenius G, Strandvik B: Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990;45:397-400.
9.
Feigelson J, Delaisi B, Pecau Y, Kerzoncuf A, Anagnostopoulos C, Tournier G: Tuberculous pneumopathy in the course of cystic fibrosis. Arch Pediatr 1997;4:1209-1212.
10.
Stiehm ER: Disease versus disease: how one disease may ameliorate another. Pediatrics 2006;117;184-191.
11.
Meindl RS: Hypothesis: a selective advantage for cystic fibrosis heterozygotes. Am J Phys Anthropol 1987;74:39-45.
12.
Rogiers V, Vercruysse A, Dab I, Baran D: Abnormal fatty acid pattern of the plasma cholesterol ester fraction in cystic fibrosis patients with and without pancreatic insufficiency. Eur J Pediatr 1983;141:39-42.
13.
Tobacman JK: Does deficiency of arylsulfatase B have a role in cystic fibrosis? Chest 2003;123:2130-2139.
14.
Asherova IK, Feigelson J, Vasilyeva LA, Gabitov VJ: Cystic fibrosis complicated by multiresistant tuberculosis. Acta Paediatr 2006;95:1513-1514.
15.
Caminero JA, Sotgiu G, Zumla A, Migliori GB: Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-629.
16.
Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.402).
17.
Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-528.
18.
Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD: Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010;65:775-783.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.